Jason S. Lewis
Memorial Sloan Kettering Cancer Center
PharmacokineticsCancerInternal medicineMolecular imagingPathologyOncologyAntibodyRadiochemistryChemistryIn vitroIn vivoPositron emission tomographyBiodistributionProstate cancerNuclear medicineCancer researchRadiation therapyStereochemistryMedicineBiology
534Publications
87H-index
18.6kCitations
Publications 524
Newest
#1Christian A. Mason (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 3
#2Grayson R. Gimblet (UAB: University of Alabama at Birmingham)
Last. Jason S. Lewis (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 87
view all 0 authors...
The use of PET imaging agents in oncology, cardiovascular disease, and neurodegenerative disease shows the power of this technique in evaluating the molecular and biological characteristics of numerous diseases. These agents provide crucial information for designing therapeutic strategies for individual patients. Novel PET tracers are in continual development and many have potential use in clinical and research settings. This article discusses the potential applications of tracers in diagnostics...
Source
#1Sai Kiran Sharma (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 16
#2Maya SuzukiH-Index: 3
Last. Nai-Kong V. Cheung (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 80
view all 11 authors...
Immuno-positron emission tomography (immuno-PET) is a powerful tool to noninvasively characterize the in vivo biodistribution of engineered antibodies (Abs). Methods null L1 cell adhesion molecule (L1CAM)-targeting HuE71 immunoglobulin G1 (IgG1) and immunoglobulin G4 (IgG4) Abs bearing identical variable heavy and light chain sequences but different fragment crystallizable (Fc) portions were radiolabeled with Zirconium-89 (89Zr) and the in vivo biodistribution was studied in SKOV3 ovarian cancer...
Source
#1Kelly E. Henry (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 4
#2Kyeara N. Mack (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 1
Last. Jason S. Lewis (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 87
view all 10 authors...
Pancreatic ductal adenocarcinoma (PDAC) patients do not benefit from immune checkpoint blockade (ICB) along the PD-1/PD-L1 axis. Variable PD-L1 expression in PDAC indicates a potential access issue of PD-L1-targeted therapy. In order to monitor target engagement of PD-L1 targeted therapy, we generated a PD-L1 targeted PET tracer labeled with zirconium-89 (89Zr). As the MAPK signaling pathway (MEK and ERK) is known to modulate PD-L1 expression in other tumor types, we used [89Zr]Zr-DFO-anti-PD-L1...
Source
#1Sai Kiran Sharma (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 16
#2Jonathan M Glaser (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 2
Last. Eric W. Price (U of S: University of Saskatchewan)H-Index: 13
view all 7 authors...
Immuno-PET using desferrioxamine (DFO)-conjugated zirconium-89 ([89Zr]Zr4+)-labeled antibodies is a powerful tool used for preclinical and clinical molecular imaging. However, a comprehensive study...
5 CitationsSource
#1Michelle T. Ma (St Thomas' Hospital)H-Index: 16
#2Jason S. Lewis (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 87
Source
#1Pereira Pmr (MSK: Memorial Sloan Kettering Cancer Center)
#2Komal Mandleywala (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 5
Last. Yelena Y. Janjigian (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 46
view all 11 authors...
Resistance mechanisms and heterogeneity in HER2-positive gastric cancers (GC) limit trastuzumab benefit in 32% of patients, and other targeted therapies have failed in clinical trials. Using genomic data from patient tissue, patient-derived xenografts (PDXs), partially humanized biological models, and HER2-targeted imaging we identified caveolin-1 (CAV1) as a complementary biomarker in GC selection for trastuzumab therapy. In retrospective analyses of samples from patients enrolled on trastuzuma...
Source
#1Andrew Chow (Cornell University)H-Index: 1
#2Sara Schad (Cornell University)H-Index: 3
Last. Marissa Mattar (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 9
view all 41 authors...
Summary null null Immune checkpoint blockade (ICB) has been a remarkable clinical advance for cancer; however, the majority of patients do not respond to ICB therapy. We show that metastatic disease in the pleural and peritoneal cavities is associated with poor clinical outcomes after ICB therapy. Cavity-resident macrophages express high levels of Tim-4, a receptor for phosphatidylserine (PS), and this is associated with reduced numbers of CD8+ T cells with tumor-reactive features in pleural eff...
1 CitationsSource
#2Komal MandleywalaH-Index: 5
Last. Jason S. LewisH-Index: 87
view all 7 authors...
Source
#1Christian A. Mason (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 3
#2Lukas M. Carter (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 10
Last. Jason S. Lewis (Cornell University)H-Index: 87
view all 10 authors...
Metastatic breast cancer is the second leading cause of cancer-related death in women. The 5-year survival rate for metastatic breast cancer has remained near 26.9 % for over a decade. The recruitment of hematopoietic stem cells with high expression of the vascular endothelial growth factor receptor 1 (VEGFR-1) has been implicated in early stages of metastasis formation. We propose the use of an 18F-labeled single-chain version of VEGF121, re-engineered to be selective for VEGFR-1 (scVR1), as a ...
Source
Source